Epigenetic Regulators Modulate Muscle Damage In Duchenne Muscular Dystrophy Model
Abstract
Histone acetyl transferases (HATs) and histone deacetylases (HDAC) control transcription during myogenesis. HDACs promote chromatin condensation, inhibiting gene transcription in muscle progenitor cells until myoblast differentiation is triggered and HDACs are released. HATs, namely CBP/p300, activate myogenic regulatory and elongation factors promoting myogenesis. HDAC inhibitors are known to improve regeneration in dystrophic muscles through follistatin upregulation. However, the potential of directly modulating HATs remains unexplored. We tested this possibility in a well-known zebrafish model of Duchenne muscular dystrophy. Interestingly, CBP/p300 transcripts were found downregulated in the absence of Dystrophin. While investigating CBP rescuing potential we observed that dystrophin-null embryos overexpressing CBP actually never show significant muscle damage, even before a first regeneration cycle could occur. We found that the pan-HDAC inhibitor trichostatin A (TSA) also prevents early muscle damage, however the single HAT CBP is as efficient even in low doses. The HAT domain of CBP is required for its full rescuing ability. Importantly, both CBP and TSA prevent early muscle damage without restoring endogenous CBP/p300 neither increasing follistatin transcripts. This suggests a new mechanism of action of epigenetic regulators protecting dystrophin-null muscle fibres from detaching, independent from the known improvement of regeneration upon damage of HDACs inhibitors. This study builds supporting evidence that epigenetic modulators may play a role in determining the severity of muscle dystrophy, controlling the ability to resist muscle damage. Determining the mode of action leading to muscle protection can potentially lead to new treatment options for muscular dystrophies in the future.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 23
- FWCI
- 0.78
- Field percentile
- top 31%
- Organism
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Partial resistance to HDAC inhibitors in FAPs of dystrophic muscles at late stages of disease is associated to epigenetic and transcriptional features of cellular senescence.
S. Consalvi, L. Tucciarone, … P. L. Puri·bioRxiv·Apr 26, 2021
- Pharmacological inhibition of HDAC6 downregulates TGF-β via Smad2/3 acetylation and improves dystrophin-deficient muscles.
A. Osseni, A. Ravel-Chapuis, … L. Schaeffer·bioRxiv·Jan 21, 2022
- Epigenetic control of myogenic identity of human muscle stem cells in Duchenne Muscular Dystrophy
Jimmy Massenet, Michèle Weiss‐Gayet, … Bénédicte Chazaud·iSciencePeer-reviewed·Nov 8, 2024
- Histone acetyltransferase inhibition rescues differentiation of emerin-null myogenic progenitors
K. A. Bossone, J. A. Ellis, J. M. Holaska·bioRxiv·Feb 25, 2020
- Epigenetic small molecule screening identifies a new HDACi compound for ameliorating Duchenne muscular dystrophy
Ke’ale W. Louie, Eva H. Hasegawa, … Lisa Maves·Molecular Therapy — Nucleic AcidsPeer-reviewed·Aug 13, 2025
- PTEN Inhibition Ameliorates Muscle Degeneration and Improves Muscle Function in a Mouse Model of Duchenne Muscular Dystrophy
Feng Yue, Changyou Song, … Shihuan Kuang·Molecular TherapyPeer-reviewed·Sep 23, 2020